SeeThruEquity Initiates Coverage on Endonovo Therapeutics, Inc. (OTCQB: ENDV) with a Price Target Price of $1.15

NEW YORK, NY / ACCESSWIRE / May 25, 2016 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage on Endonovo Therapeutics, Inc. (OTCQB: ENDV) with a price target of $1.15.

The report is available here: ENDV Initiation Report. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack’s. The report will be available on these platforms. The firm also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

Based in Los Angeles, CA Endonovo is a biotechnology company focused on developing bioelectrical devices and therapies for regenerative medicine. Endonovo is developing two new platform technologies that utilize time-varying electromagnetic fields (TVEMF). These include the company’s Immunotronics™ Platform, a non-invasive medical device for the treatment and prevention of organ failure, and its Cytotronics™ Platform, an application of TVEMF to enhance and expand cells and potentially for the development of fully human biologics. Endonovo will initially develop therapies from these platforms addressing rare diseases, which should expedite development time if Endonovo can secure a Humanitarian Device Exemption for its Immunotronics™ device for acute liver failure, and an Orphan Drug Designation for its Cytotronics™ cell therapy for graft versus host disease (GVHD). However, we believe the company’s broader goal is to show that its Immunotronics technology has very large potential to change the way we treat inflammation and prevent organ failure. We view Endonovo as a speculative company in the biotechnology market with high risk and high growth potential from the large markets targeted by its intriguing and potentially disruptive Immunotronics™ and Cytotronics™ platforms.

“Endonovo is led by a committed management team with significant experience in the industry. The company is led by CEO and Chairman Alan Collier, who brings over 20 years of experience in corporate finance, technology and IP development. Collier joined the company in 2011. His previous roles include founding IP Resources International, where he developed a platform for licensing and acquiring technology for life sciences and technology companies. The company’s Chief Medical Officer is Leonard Makowka, MD, PhD. Dr. Makowka has been published over 400 times and is known in the medical community, having served as Executive Director at the Comprehensive Liver Disease Center at St. Vincent’s Medical Center as well as serving as a member of the Board of Directors at multiple publicly listed companies. Endonovo also benefits from the financial and operations experience of President Michael Scott Mann and COO Don Calabria, who joined the company in 2012 and 2011, respectively, and each bring Endonovo over 20 years of relevant leadership experience. We have included full bios of Endonovo’s top management on pages 10-11 of this report,” stated Ajay Tandon, CEO of SeeThruEquity. “We are initiating coverage with a 12-month price target of $1.15 per share.”

Additional highlights from the report are as follows:

Next 12-18 months a key time for Endonovo

We see the next 12-18 months as being an important time for Endonovo. As of the end of 2015, Endonovo been funded with approximately $2.8mn of capital, and management is in the process of raising an additional round of $2mn – $5mn, which would be used to advance its platforms into clinical trials. Indeed, the company has several potential milestones in the next year. For the Immunotronics™ platform, these include the initiation of a rat liver trial, which is expected to commence in 2H16, as well as an application for an investigational device exemption (IDE) for acute liver failure (early 2017E).

For the Cytotronics™ Platform, the next key milestones that would be enabled by this funding would be the potential granting of an orphan drug designation (estimated 1H2017E) from the FDA for its next generation off-the-shelf treatment for GVHD. Assuming management is able to execute on these initiatives, we would expect this to set up another and potentially larger raise for 2017E. The purpose of this raise would be to fund human studies for the Immunotronics™ device, which would possibly done in conjunction with a reverse split and an attempt to list shares on a national exchange such as the NYSE MKT or NASDAQ.

Initiate coverage with a price target of $1.15

Our analysis of Endonovo indicates a fair value estimate of $1.15 per share (detailed on pages 8-9), implying an upside of 150.0% from the recent price of $0.50. We view Endonovo as a speculative company in the biotechnology market with high risk and high growth potential from the large markets targeted by its intriguing and potentially disruptive Immunotronics™ and Cytotronics™ platforms.

Please review important disclosures at www.seethruequity.com.

About Endonovo Therapeutics, Inc.

Endonovo Therapeutics, Inc. is an innovative biotechnology company developing bioelectronic devices and therapies for regenerative medicine. Endonovo’s Immunotronics™ platform is a non-invasive, non-implantable bioelectronic device for treating/preventing vital organ failure through the reduction of inflammation, cell death and the promotion of regeneration. Endonovo’s Cytotronics™ platform provides for a method of expanding and manipulating cells using simulated microgravity and Time-Varying Electromagnetic Fields (TVEMF) for tissue engineering and cell therapies. The Company’s initial concentration is on the treatment of acute and chronic inflammatory conditions of the liver using its proprietary Immunotronics™ platform.

About SeeThruEquity

SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. The company does not conduct any investment banking or commission based business. SeeThruEquity is approved to contribute its research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks, and distribute its research to its database of opt-in investors. The company also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

For more information visit www.seethruequity.com.

Contact:

Ajay Tandon
SeeThruEquity
info@seethruequity.com

SOURCE: SeeThruEquity

ReleaseID: 440383